Protocol Number: 03-C-0202
- The highest dose of G3139 that can be given safely to children and adolescents with cancer; - The side effects of G3139 given together with doxorubicin and cyclophosphamide; - The pharmacology of G3139; that is, how the body handles the drug; - The effects of G3139 on blood levels of Bcl-2; - The level of Bcl-2 in the child's tumor and the effects of G3139 on the Bcl-2 in the tumor; - Whether G3139, together with doxorubicin and cyclophosphamide can inhibit the growth of the cancer. Children with solid tumors, except central nervous system tumors and lymphomas, whose cancer no longer responds to standard treatment or for whom standard therapy is not available may be eligible for this study. Participants will receive a continuous infusion of G3139 into a vein for 7 days. On days 5 and 6, they will also receive doxorubicin, cyclophosphamide and dexrazoxane. (The latter drug protects the heart from possible damage from doxorubicin.) After 14 days off drugs, the children will begin a second 21-day treatment cycle. Treatment will continue for up to 18 cycles (about 1 year) as long as the tumor does not worsen and there are no serious side effects. The children will be hospitalized for the first 8 or 9 days of the first cycle to monitor treatment side effects. For the infusions, children will need a central venous catheter - a plastic tube placed into a major vein in the chest. This line can stay in the body and be used for the entire treatment period to give chemotherapy or other medications and to draw blood samples. The line is usually placed under local anesthesia in the radiology department or the operating room. In addition to drug treatment, patients will have the following tests and procedures: - Examinations by a doctor at least once a week and routine blood tests twice a week during the first 21-day treatment cycle. - Physical examinations, routine blood tests, and imaging tests (e.g., x-rays, CT scans, MRI scans) periodically throughout the course of treatment after the first cycle to evaluate the response to treatment and treatment side effects. - Blood samples for a pharmacology study during the first treatment cycle (optional). This requires taking 12 separate blood samples of 1/2 teaspoon each-one each on days 1, 5, and 6 of the infusion; 7 samples on day 8, when the infusion ends (every 1/2-hour for 8 hours); and two samples on day 9. - Blood samples to test white blood cells to examine the effect of G3139 on normal cells (optional). This requires taking blood samples on days 1, 5, 6, and 8 of the first treatment cycle. - Tumor tissue tests to determine if cancer cells have increased Bcl-2 levels (optional). These tests are performed on frozen tissue samples obtained during surgery or biopsy, if these procedures are required for the child's care during the time of this study.
Search The Studies | Help | Questions |
Warren Grant Magnuson Clinical Center (CC) |
||